Douglas Earl Martin's Form 4 filing
Allogene Therapeutics, Inc. (ALLO) · filed Aug 25, 2026
- Accession no.
- 0001628280-26-058920
- Filed
- Aug 25, 2026, 4:43 PM ET
- Trade date
- Aug 21, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $63.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Douglas Earl MartinCIK 0001362155 | Officer (SVP, General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Common Stock | SSaleDisposed | −29,697 | $2.12 | −$62,957.64 | 488,267 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.